NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: NASDAQ:) at this time introduced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will take part within the Jefferies Global Healthcare Conference, being held on the Marriott Marquis, in New York City on June 5-6, 2024. The fireplace chat is scheduled to happen on Wednesday, June 5, 2024, at 1:30 PM ET.

A stay webcast of the hearth chat will likely be out there on the Events web page, situated throughout the Investors & Media part, of the Company’s web site at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICSTG Therapeutics is a completely built-in, business stage, biopharmaceutical firm centered on the acquisition, growth and commercialization of novel therapies for B-cell ailments. In addition to a analysis pipeline together with a number of investigational medicines, TG has acquired U.S. Food and Drug Administration (FDA) approval for BRIUMVI ® (ublituximab-xiiy), for the remedy of grownup sufferers with relapsing types of a number of sclerosis (RMS), to incorporate clinically remoted syndrome, relapsing-remitting illness, and energetic secondary progressive illness, in addition to approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to deal with grownup sufferers with RMS who’ve energetic illness outlined by scientific or imaging options in Europe and the United Kingdom, respectively. For extra data, go to www.tgtherapeutics.com, and observe us on X (previously Twitter) @TGTherapeutics and on LinkedIn.

BRIUMVI ® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor RelationsEmail: ir@tgtxinc.com  Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:Email: media@tgtxinc.com  Telephone: 1.877.575.TGTX (8489), Option 6

Source: TG Therapeutics, Inc.
MoneyMaker FX EA Trading Robot

powered by qhost365.com

Investing.com